NEW YORK (GenomeWeb) – Quark Pharmaceuticals this week presented data from a Phase II trial of QPI-1002, an siRNA-based drug for the prevention of delayed graft function (DGF) in kidney transplant patients.
NEW YORK (GenomeWeb) – Quark Pharmaceuticals this week announced that it has completed a Phase II trial of its siRNA-based drug for the prevention of delayed graft function in kidney transplant patients.
While RNAi drug developers continue to pursue major indications such as cancer and hepatitis C, a number of these companies are looking to niche diseases as good opportunities to apply the gene-silencing technology.
The provisions for the EU orphan designation provide incentives to companies developing orphan drugs, including the potential for up to 10 years of market exclusivity and various fee reductions for certain regulatory activities, Quark said.
The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.